Advertisement

Gastrointestinal Involvement of Systemic Sclerosis

  • Hiroshi WatanabeEmail author
Chapter

Abstract

Systemic sclerosis (SSc) is a rare autoimmune disease characterized by microvascular abnormalities that result in fibrosis of the skin and other organs. Gastrointestinal (GI) manifestations are frequently observed in patients with SSc and occur in both diffuse cutaneous SSc and limited cutaneous SSc. The entire GI tract displays the pathological findings of SSc, including vasculopathy, smooth muscle atrophy, and excessive collagen deposition in the submucosa. As SSc progresses, the GI manifestations not only impair the quality of life by causing symptoms such as pain, nausea, vomiting, constipation, and fecal incontinence but are also related to poor prognosis. At present, the management of GI manifestations in patients with SSc is empirical and symptomatic. The goals of the treatment are the prevention of malnutrition and improvement of the quality of life.

Keywords

Systemic sclerosis Gastrointestinal involvement 

References

  1. 1.
    Braun-Moscovici Y, Brun R, Braun M. Systemic sclerosis and the gastrointestinal tract-clinical approach. Rambam Maimonides Med J. 2016;7(4):e0031.PubMedCentralCrossRefGoogle Scholar
  2. 2.
    Turner R, Lipshutz W, Miller W, Rittenberg G, Schumacher HR, Cohen S. Esophageal dysfunction in collagen disease. Am J Med Sci. 1973;265(3):191–9.PubMedCrossRefGoogle Scholar
  3. 3.
    Akesson A, Wollheim FA. Organ manifestations in 100 patients with progressive systemic sclerosis: a comparison between the CREST syndrome and diffuse scleroderma. Br J Rheumatol. 1989;28(4):281–6.PubMedCrossRefGoogle Scholar
  4. 4.
    Forbes A, Marie I. Gastrointestinal complications: the most frequent internal complications of systemic sclerosis. Rheumatology (Oxford). 2009;48(Suppl 3):iii36–9.Google Scholar
  5. 5.
    Tiev KP, Cabane J. Digestive tract involvement in systemic sclerosis. Autoimmun Rev. 2011;11(1):68–73.PubMedCrossRefGoogle Scholar
  6. 6.
    Tian XP, Zhang X. Gastrointestinal complications of systemic sclerosis. World J Gastroenterol. 2013;19(41):7062–8.PubMedPubMedCentralCrossRefGoogle Scholar
  7. 7.
    McFarlane IM, Bhamra MS, Kreps A, Iqbal S, Al-Ani F, Saladini-Aponte C, et al. Gastrointestinal manifestations of systemic sclerosis. Rheumatology (Sunnyvale). 2018;8(1):235.CrossRefGoogle Scholar
  8. 8.
    Altman RD, Medsger TA Jr, Bloch DA, Michel BA. Predictors of survival in systemic sclerosis (scleroderma). Arthritis Rheum. 1991;34(4):403–13.PubMedCrossRefGoogle Scholar
  9. 9.
    Steen VD, Medsger TA Jr. Severe organ involvement in systemic sclerosis with diffuse scleroderma. Arthritis Rheum. 2000;43(11):2437–44.PubMedCrossRefGoogle Scholar
  10. 10.
    Sjogren RW. Gastrointestinal motility disorders in scleroderma. Arthritis Rheum. 1994;37(9):1265–82.PubMedCrossRefGoogle Scholar
  11. 11.
    Jaovisidha K, Csuka ME, Almagro UA, Soergel KH. Severe gastrointestinal involvement in systemic sclerosis: report of five cases and review of the literature. Semin Arthritis Rheum. 2005;34(4):689–702.PubMedCrossRefGoogle Scholar
  12. 12.
    Nishimagi E, Tochimoto A, Kawaguchi Y, Satoh T, Kuwana M, Takagi K, et al. Characteristics of patients with early systemic sclerosis and severe gastrointestinal tract involvement. J Rheumatol. 2007;34(10):2050–5.PubMedGoogle Scholar
  13. 13.
    Howe S, Eaker EY, Sallustio JE, Peebles C, Tan EM, Williams RC Jr. Antimyenteric neuronal antibodies in scleroderma. J Clin Invest. 1994;94(2):761–70.PubMedPubMedCentralCrossRefGoogle Scholar
  14. 14.
    Goldblatt F, Gordon TP, Waterman SA. Antibody-mediated gastrointestinal dysmotility in scleroderma. Gastroenterology. 2002;123(4):1144–50.PubMedCrossRefGoogle Scholar
  15. 15.
    Singh J, Mehendiratta V, Del Galdo F, Jimenez SA, Cohen S, DiMarino AJ, et al. Immunoglobulins from scleroderma patients inhibit the muscarinic receptor activation in internal anal sphincter smooth muscle cells. Am J Physiol Gastrointest Liver Physiol. 2009;297(6):G1206–13.PubMedPubMedCentralCrossRefGoogle Scholar
  16. 16.
    Singh J, Cohen S, Mehendiratta V, Mendoza F, Jimenez SA, Dimarino AJ, et al. Effects of scleroderma antibodies and pooled human immunoglobulin on anal sphincter and colonic smooth muscle function. Gastroenterology. 2012;143(5):1308–18.PubMedPubMedCentralCrossRefGoogle Scholar
  17. 17.
    Roberts CG, Hummers LK, Ravich WJ, Wigley FM, Hutchins GM. A case-control study of the pathology of oesophageal disease in systemic sclerosis (scleroderma). Gut. 2006;55(12):1697–703.PubMedPubMedCentralCrossRefGoogle Scholar
  18. 18.
    Thonhofer R, Siegel C, Trummer M, Graninger W. Early endoscopy in systemic sclerosis without gastrointestinal symptoms. Rheumatol Int. 2012;32(1):165–8.PubMedCrossRefGoogle Scholar
  19. 19.
    Wipff J, Allanore Y, Soussi F, Terris B, Abitbol V, Raymond J, et al. Prevalence of Barrett’s esophagus in systemic sclerosis. Arthritis Rheum. 2005;52(9):2882–8.PubMedCrossRefGoogle Scholar
  20. 20.
    Miller JB, Gandhi N, Clarke J, McMahan Z. Gastrointestinal involvement in systemic sclerosis: an update. J Clin Rheumatol. 2018;24(6):328–37.PubMedCrossRefGoogle Scholar
  21. 21.
    Savarino E, Bazzica M, Zentilin P, Pohl D, Parodi A, Cittadini G, et al. Gastroesophageal reflux and pulmonary fibrosis in scleroderma: a study using pH-impedance monitoring. Am J Respir Crit Care Med. 2009;179(5):408–13.PubMedCrossRefGoogle Scholar
  22. 22.
    Johnson DA, Drane WE, Curran J, Cattau EL Jr, Ciarleglio C, Khan A, et al. Pulmonary disease in progressive systemic sclerosis. A complication of gastroesophageal reflux and occult aspiration? Arch Intern Med. 1989;149(3):589–93.PubMedCrossRefGoogle Scholar
  23. 23.
    Zhang XJ, Bonner A, Hudson M, Canadian Scleroderma Research Group, Baron M, Pope J. Association of gastroesophageal factors and worsening of forced vital capacity in systemic sclerosis. J Rheumatol. 2013;40(6):850–8.PubMedCrossRefGoogle Scholar
  24. 24.
    Christmann RB, Wells AU, Capelozzi VL, Silver RM. Gastroesophageal reflux incites interstitial lung disease in systemic sclerosis: clinical, radiologic, histopathologic, and treatment evidence. Semin Arthritis Rheum. 2010;40(3):241–9.PubMedCrossRefGoogle Scholar
  25. 25.
    Marie I, Levesque H, Ducrotte P, Denis P, Hellot MF, Benichou J, et al. Gastric involvement in systemic sclerosis: a prospective study. Am J Gastroenterol. 2001;96(1):77–83.PubMedCrossRefGoogle Scholar
  26. 26.
    Sridhar KR, Lange RC, Magyar L, Soykan I, McCallum RW. Prevalence of impaired gastric emptying of solids in systemic sclerosis: diagnostic and therapeutic implications. J Lab Clin Med. 1998;132(6):541–6.PubMedCrossRefGoogle Scholar
  27. 27.
    Franck-Larsson K, Hedenstrom H, Dahl R, Ronnblom A. Delayed gastric emptying in patients with diffuse versus limited systemic sclerosis, unrelated to gastrointestinal symptoms and myoelectric gastric activity. Scand J Rheumatol. 2003;32(6):348–55.PubMedCrossRefGoogle Scholar
  28. 28.
    Hung EW, Mayes MD, Sharif R, Assassi S, Machicao VI, Hosing C, et al. Gastric antral vascular ectasia and its clinical correlates in patients with early diffuse systemic sclerosis in the SCOT trial. J Rheumatol. 2013;40(4):455–60.PubMedPubMedCentralCrossRefGoogle Scholar
  29. 29.
    Komiyama M, Fu K, Morimoto T, Konuma H, Yamagata T, Izumi Y, et al. A novel endoscopic ablation of gastric antral vascular ectasia. World J Gastrointest Endosc. 2010;2(8):298–300.PubMedPubMedCentralCrossRefGoogle Scholar
  30. 30.
    Marie I, Ducrotte P, Denis P, Hellot MF, Levesque H. Outcome of small-bowel motor impairment in systemic sclerosis—a prospective manometric 5-yr follow-up. Rheumatology (Oxford). 2007;46(1):150–3.CrossRefGoogle Scholar
  31. 31.
    Savarino E, Mei F, Parodi A, Ghio M, Furnari M, Gentile A, et al. Gastrointestinal motility disorder assessment in systemic sclerosis. Rheumatology (Oxford). 2013;52(6):1095–100.CrossRefGoogle Scholar
  32. 32.
    Ponge T, Bruley des Varannes S. [Digestive involvement of scleroderma]. Rev Prat. 2002;52(17):1896–900.Google Scholar
  33. 33.
    Sallam H, McNearney TA, Chen JD. Systematic review: pathophysiology and management of gastrointestinal dysmotility in systemic sclerosis (scleroderma). Aliment Pharmacol Ther. 2006;23(6):691–712.PubMedCrossRefGoogle Scholar
  34. 34.
    Gregersen H, Liao D, Pedersen J, Drewes AM. A new method for evaluation of intestinal muscle contraction properties: studies in normal subjects and in patients with systemic sclerosis. Neurogastroenterol Motil. 2007;19(1):11–9.PubMedCrossRefGoogle Scholar
  35. 35.
    Gyger G, Baron M. Gastrointestinal manifestations of scleroderma: recent progress in evaluation, pathogenesis, and management. Curr Rheumatol Rep. 2012;14(1):22–9.PubMedCrossRefGoogle Scholar
  36. 36.
    Bures J, Cyrany J, Kohoutova D, Forstl M, Rejchrt S, Kvetina J, et al. Small intestinal bacterial overgrowth syndrome. World J Gastroenterol. 2010;16(24):2978–90.PubMedPubMedCentralCrossRefGoogle Scholar
  37. 37.
    Valenzuela A, Li S, Becker L, Fernandez-Becker N, Khanna D, Nguyen L, et al. Intestinal pseudo-obstruction in patients with systemic sclerosis: an analysis of the Nationwide Inpatient Sample. Rheumatology (Oxford). 2016;55(4):654–8.CrossRefGoogle Scholar
  38. 38.
    Gasbarrini A, Lauritano EC, Gabrielli M, Scarpellini E, Lupascu A, Ojetti V, et al. Small intestinal bacterial overgrowth: diagnosis and treatment. Dig Dis. 2007;25(3):237–40.PubMedCrossRefGoogle Scholar
  39. 39.
    Pimentel M, Chow EJ, Lin HC. Normalization of lactulose breath testing correlates with symptom improvement in irritable bowel syndrome. a double-blind, randomized, placebo-controlled study. Am J Gastroenterol. 2003;98(2):412–9.PubMedGoogle Scholar
  40. 40.
    Kaneko M, Sasaki S, Teruya S, Ozaki K, Ishimaru K, Terai E, et al. Pneumatosis cystoides intestinalis in patients with systemic sclerosis: a case report and review of 39 Japanese cases. Case Rep Gastrointest Med. 2016;2016:2474515.PubMedPubMedCentralGoogle Scholar
  41. 41.
    Kinjo M. Lurking in the wall: pneumatosis cystoides intestinalis with scleroderma. Am J Med. 2016;129(4):382–3.PubMedCrossRefGoogle Scholar
  42. 42.
    Wu LL, Yang YS, Dou Y, Liu QS. A systematic analysis of pneumatosis cystoids intestinalis. World J Gastroenterol. 2013;19(30):4973–8.PubMedPubMedCentralCrossRefGoogle Scholar
  43. 43.
    Thoua NM, Schizas A, Forbes A, Denton CP, Emmanuel AV. Internal anal sphincter atrophy in patients with systemic sclerosis. Rheumatology (Oxford). 2011;50(9):1596–602.CrossRefGoogle Scholar
  44. 44.
    Trezza M, Krogh K, Egekvist H, Bjerring P, Laurberg S. Bowel problems in patients with systemic sclerosis. Scand J Gastroenterol. 1999;34(4):409–13.PubMedCrossRefGoogle Scholar
  45. 45.
    Thoua NM, Abdel-Halim M, Forbes A, Denton CP, Emmanuel AV. Fecal incontinence in systemic sclerosis is secondary to neuropathy. Am J Gastroenterol. 2012;107(4):597–603.PubMedCrossRefGoogle Scholar
  46. 46.
    Malandrini A, Selvi E, Villanova M, Berti G, Sabadini L, Salvadori C, et al. Autonomic nervous system and smooth muscle cell involvement in systemic sclerosis: ultrastructural study of 3 cases. J Rheumatol. 2000;27(5):1203–6.PubMedGoogle Scholar
  47. 47.
    Compton R. Scleroderma with diverticulosis and colonic obstruction. Am J Surg. 1969;118(4):602–6.PubMedCrossRefGoogle Scholar
  48. 48.
    Katz PO, Gerson LB, Vela MF. Guidelines for the diagnosis and management of gastroesophageal reflux disease. Am J Gastroenterol. 2013;108(3):308–28; quiz 29.PubMedCrossRefGoogle Scholar
  49. 49.
    Hostein J, Li V, Carpentier P, Fournet J. [Omeprazole: crucial progress in the treatment of esophagitis in progressive systemic scleroderma]. Gastroenterol Clin Biol. 1991;15(5):460–1.Google Scholar
  50. 50.
    Pakozdi A, Wilson H, Black CM, Denton CP. Does long term therapy with lansoprazole slow progression of oesophageal involvement in systemic sclerosis? Clin Exp Rheumatol. 2009;27(3 Suppl 54):5–8.PubMedGoogle Scholar
  51. 51.
    Mercado U, Arroyo de Anda R, Avendano L, Araiza-Casillas R, Avendano-Reyes M. Metoclopramide response in patients with early diffuse systemic sclerosis. Effects on esophageal motility abnormalities. Clin Exp Rheumatol. 2005;23(5):685–8.PubMedGoogle Scholar
  52. 52.
    Johnson DA, Drane WE, Curran J, Benjamin SB, Chobanian SJ, Karvelis K, et al. Metoclopramide response in patients with progressive systemic sclerosis. Effect on esophageal and gastric motility abnormalities. Arch Intern Med. 1987;147(9):1597–601.PubMedCrossRefGoogle Scholar
  53. 53.
    Ramirez-Mata M, Ibanez G, Alarcon-Segovia D. Stimulatory effect of metoclopramide on the esophagus and lower esophageal sphincter of patients of patients with PSS. Arthritis Rheum. 1977;20(1):30–4.PubMedCrossRefGoogle Scholar
  54. 54.
    Camilleri M, Parkman HP, Shafi MA, Abell TL, Gerson L, American College of Gastroenterology. Clinical guideline: management of gastroparesis. Am J Gastroenterol. 2013;108(1):18–37; quiz 8.PubMedCrossRefGoogle Scholar
  55. 55.
    Snape WJ Jr, Battle WM, Schwartz SS, Braunstein SN, Goldstein HA, Alavi A. Metoclopramide to treat gastroparesis due to diabetes mellitus: a double-blind, controlled trial. Ann Intern Med. 1982;96(4):444–6.PubMedCrossRefGoogle Scholar
  56. 56.
    Ricci DA, Saltzman MB, Meyer C, Callachan C, McCallum RW. Effect of metoclopramide in diabetic gastroparesis. J Clin Gastroenterol. 1985;7(1):25–32.PubMedCrossRefGoogle Scholar
  57. 57.
    McCallum RW, Ricci DA, Rakatansky H, Behar J, Rhodes JB, Salen G, et al. A multicenter placebo-controlled clinical trial of oral metoclopramide in diabetic gastroparesis. Diabetes Care. 1983;6(5):463–7.PubMedCrossRefGoogle Scholar
  58. 58.
    Patterson D, Abell T, Rothstein R, Koch K, Barnett J. A double-blind multicenter comparison of domperidone and metoclopramide in the treatment of diabetic patients with symptoms of gastroparesis. Am J Gastroenterol. 1999;94(5):1230–4.PubMedGoogle Scholar
  59. 59.
    Janssens J, Peeters TL, Vantrappen G, Tack J, Urbain JL, De Roo M, et al. Improvement of gastric emptying in diabetic gastroparesis by erythromycin. Preliminary studies. N Engl J Med. 1990;322(15):1028–31.PubMedCrossRefGoogle Scholar
  60. 60.
    Boeckxstaens GE, Bartelsman JF, Lauwers L, Tytgat GN. Treatment of GI dysmotility in scleroderma with the new enterokinetic agent prucalopride. Am J Gastroenterol. 2002;97(1):194–7.PubMedCrossRefGoogle Scholar
  61. 61.
    Takahashi T, Endo S, Nakajima K, Souma Y, Nishida T. Effect of rikkunshito, a chinese herbal medicine, on stasis in patients after pylorus-preserving gastrectomy. World J Surg. 2009;33(2):296–302.PubMedCrossRefGoogle Scholar
  62. 62.
    Ingraham KM, O'Brien MS, Shenin M, Derk CT, Steen VD. Gastric antral vascular ectasia in systemic sclerosis: demographics and disease predictors. J Rheumatol. 2010;37(3):603–7.PubMedCrossRefGoogle Scholar
  63. 63.
    Marie I, Ducrotte P, Antonietti M, Herve S, Levesque H. Watermelon stomach in systemic sclerosis: its incidence and management. Aliment Pharmacol Ther. 2008;28(4):412–21.PubMedCrossRefGoogle Scholar
  64. 64.
    Nagaraja V, McMahan ZH, Getzug T, Khanna D. Management of gastrointestinal involvement in scleroderma. Curr Treatm Opt Rheumatol. 2015;1(1):82–105.PubMedPubMedCentralCrossRefGoogle Scholar
  65. 65.
    Lauritano EC, Gabrielli M, Scarpellini E, Ojetti V, Roccarina D, Villita A, et al. Antibiotic therapy in small intestinal bacterial overgrowth: rifaximin versus metronidazole. Eur Rev Med Pharmacol Sci. 2009;13(2):111–6.PubMedGoogle Scholar
  66. 66.
    Frech TM, Khanna D, Maranian P, Frech EJ, Sawitzke AD, Murtaugh MA. Probiotics for the treatment of systemic sclerosis-associated gastrointestinal bloating/distention. Clin Exp Rheumatol. 2011;29(2 Suppl 65):S22–5.PubMedGoogle Scholar
  67. 67.
    Rees WD, Leigh RJ, Christofides ND, Bloom SR, Turnberg LA. Interdigestive motor activity in patients with systemic sclerosis. Gastroenterology. 1982;83(3):575–80.PubMedGoogle Scholar
  68. 68.
    Nikou GC, Toumpanakis C, Katsiari C, Charalambopoulos D, Sfikakis PP. Treatment of small intestinal disease in systemic sclerosis with octreotide: a prospective study in seven patients. J Clin Rheumatol. 2007;13(3):119–23.PubMedCrossRefGoogle Scholar
  69. 69.
    Verne GN, Eaker EY, Hardy E, Sninsky CA. Effect of octreotide and erythromycin on idiopathic and scleroderma-associated intestinal pseudoobstruction. Dig Dis Sci. 1995;40(9):1892–901.PubMedCrossRefGoogle Scholar
  70. 70.
    Kenefick NJ, Vaizey CJ, Nicholls RJ, Cohen R, Kamm MA. Sacral nerve stimulation for faecal incontinence due to systemic sclerosis. Gut. 2002;51(6):881–3.PubMedPubMedCentralCrossRefGoogle Scholar

Copyright information

© Springer Nature Singapore Pte Ltd. 2019

Authors and Affiliations

  1. 1.Department of RheumatologyFukushima Medical University School of MedicineFukushimaJapan

Personalised recommendations